OSTX OS Therapies Incorporated
OS Therapies Incorporated (OSTX) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.5% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About OS Therapies Incorporated
OS Therapies Incorporated is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. The company's lead asset consists OST-HER2. OS Therapies Incorporated is based in NEW YORK.
Sector
Healthcare
Industry
Biotechnology